We are analyzing https://link.springer.com/article/10.1186/s12885-022-09313-w.

Title:
Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma | BMC Cancer
Description:
Background Low-grade glioma (LGG) is susceptible to ferroptosis, which is involved in TMZ resistance. Ferroptosis induction can enhance the sensitivity to TMZ and synergistically kill glioma cells. T cell-promoted tumor ferroptosis is a vital anti-tumor mechanism of immune checkpoint inhibitors. The SAT1 activation is closely related to ferroptosis upon ROS induction due to the upregulation of arachidonate 15-lipoxygenase (ALOX15) expression. Methods The expression of SAT1 in pan-cancer and corresponding normal tissue from the TCGA data portal was primarily explored. The landscape of SAT1 and immune cell infiltration and their corresponding gene marker sets in different tissues were further explored. Additionally, we evaluated the relationships between SAT1 and the clinicopathologic parameters of LGG, and the disease-specific survival (DSS), progression-free interval (PFI), and overall survival (OS) were also assessed using KM survival curves and multivariate analysis in LGG. Meanwhile, the Gene Set Enrichment Analysis (GSEA) was also implemented to determine the potential effect of the SAT1 gene in LGG. Furthermore, the predictive power of SAT1 was validated using an independent LGG cohort from the Chinese Glioma Genome Atlas (CGGA) data. Results In general, the expression of SAT1 is different between most tumors and their adjacent normal tissues. The results demonstrated that SAT1 expression is positively associated with TMB in LGG, BRCA, and THYM. The results displayed that the expression level of SAT1 is obviously correlated with the level of infiltrating macrophages and CD8 + T cells, and the levels of most immune gene sets were associated with the SAT1 expression in LGG. Interestingly, univariate and multivariate models significantly indicated that the OS and PFI of patients with LGG with high SAT1 levels were poorer than those with low SAT1 expression in the TCGA LGG cohort. GSEA showed that SAT1 was involved in immune regulation and multiple signaling pathways. Finally, our analysis demonstrated that SAT1 was closely associated with IDH mutation, 1p19q codeletion, chemoradiotherapy resistance and disease recurrence. Conclusions Abundant expression of SAT1 was related to poor disease prognosis and abundant immune cell infiltration in LGG.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

sat, expression, lgg, immune, cells, cell, pubmed, article, ferroptosis, cancer, glioma, analysis, epub, data, patients, fig, google, scholar, gene, levels, tumor, cas, types, idh, survival, central, prognostic, related, infiltration, results, tmb, prognosis, clinical, immunotherapy, tissues, correlated, mrna, normal, correlation, cgga, mutation, relationship, research, zhang, tumors, genes, carcinoma, journal, full, explored,

Topics {✒️}

�single-cell multi-omics profiling t-cell activation lymphoma cell line kaplan–meier survival plot nonsteroidal anti-inflammatory drugs time-dependent roc curve kaplan–meier survival curves p53-mediated ferroptotic responses spermidine/spermine n-1 acetyltransferase inhibitory cd161–clec2d pathway article download pdf user-friendly web application central nervous system analyzing multi-omics data polyamine regulator spermidine/spermine kaplan–meier survival analysis time-dependent roc analyses pan-cancer tumor tissues spermidine/spermine n1-acetyltransferase 1 gene-specific transcriptional regulator expression rna-seq data lung cancer cells low-grade glioma immune checkpoint blockade cell-promoted tumor ferroptosis vital anti-tumor mechanism potential immunological therapy targets cell–mediated killing immune-related gene characteristics tumor-infiltrating immune cells xiangyang central hospital immune checkpoint inhibitors aggressive surgical operation coexpressed gene information curcumin/temozolomide combination therapy privacy choices/manage cookies key metabolic regulator sat1-knockout substantially eliminated immune cell enrichment kaplan–meier method brett-morris glioma groups based special access privileges low expression levels brain glial tumors chemokine signaling pathway gene marker sets pathway enrichment analysis time-dependent roc single cell portal

Questions {❓}

Immunotherapy for glioma: from illusion to realistic prospects?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma
         description:Low-grade glioma (LGG) is susceptible to ferroptosis, which is involved in TMZ resistance. Ferroptosis induction can enhance the sensitivity to TMZ and synergistically kill glioma cells. T cell-promoted tumor ferroptosis is a vital anti-tumor mechanism of immune checkpoint inhibitors. The SAT1 activation is closely related to ferroptosis upon ROS induction due to the upregulation of arachidonate 15-lipoxygenase (ALOX15) expression. The expression of SAT1 in pan-cancer and corresponding normal tissue from the TCGA data portal was primarily explored. The landscape of SAT1 and immune cell infiltration and their corresponding gene marker sets in different tissues were further explored. Additionally, we evaluated the relationships between SAT1 and the clinicopathologic parameters of LGG, and the disease-specific survival (DSS), progression-free interval (PFI), and overall survival (OS) were also assessed using KM survival curves and multivariate analysis in LGG. Meanwhile, the Gene Set Enrichment Analysis (GSEA) was also implemented to determine the potential effect of the SAT1 gene in LGG. Furthermore, the predictive power of SAT1 was validated using an independent LGG cohort from the Chinese Glioma Genome Atlas (CGGA) data. In general, the expression of SAT1 is different between most tumors and their adjacent normal tissues. The results demonstrated that SAT1 expression is positively associated with TMB in LGG, BRCA, and THYM. The results displayed that the expression level of SAT1 is obviously correlated with the level of infiltrating macrophages and CD8 + T cells, and the levels of most immune gene sets were associated with the SAT1 expression in LGG. Interestingly, univariate and multivariate models significantly indicated that the OS and PFI of patients with LGG with high SAT1 levels were poorer than those with low SAT1 expression in the TCGA LGG cohort. GSEA showed that SAT1 was involved in immune regulation and multiple signaling pathways. Finally, our analysis demonstrated that SAT1 was closely associated with IDH mutation, 1p19q codeletion, chemoradiotherapy resistance and disease recurrence. Abundant expression of SAT1 was related to poor disease prognosis and abundant immune cell infiltration in LGG.
         datePublished:2022-02-28T00:00:00Z
         dateModified:2022-02-28T00:00:00Z
         pageStart:1
         pageEnd:15
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12885-022-09313-w
         keywords:
            Ferroptosis
            SAT1
            Low-grade glioma
            Pan-cancer
            Immune cells
            Immune checkpoint
            Drug resistance
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig7_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig8_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig9_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig10_HTML.png
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:22
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yanhua Mou
               affiliation:
                     name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
                     address:
                        name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lu Zhang
               affiliation:
                     name:First Affiliated Hospital of Anhui Medical University
                     address:
                        name:Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zhantao Liu
               affiliation:
                     name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
                     address:
                        name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Xiujun Song
               affiliation:
                     name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
                     address:
                        name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma
      description:Low-grade glioma (LGG) is susceptible to ferroptosis, which is involved in TMZ resistance. Ferroptosis induction can enhance the sensitivity to TMZ and synergistically kill glioma cells. T cell-promoted tumor ferroptosis is a vital anti-tumor mechanism of immune checkpoint inhibitors. The SAT1 activation is closely related to ferroptosis upon ROS induction due to the upregulation of arachidonate 15-lipoxygenase (ALOX15) expression. The expression of SAT1 in pan-cancer and corresponding normal tissue from the TCGA data portal was primarily explored. The landscape of SAT1 and immune cell infiltration and their corresponding gene marker sets in different tissues were further explored. Additionally, we evaluated the relationships between SAT1 and the clinicopathologic parameters of LGG, and the disease-specific survival (DSS), progression-free interval (PFI), and overall survival (OS) were also assessed using KM survival curves and multivariate analysis in LGG. Meanwhile, the Gene Set Enrichment Analysis (GSEA) was also implemented to determine the potential effect of the SAT1 gene in LGG. Furthermore, the predictive power of SAT1 was validated using an independent LGG cohort from the Chinese Glioma Genome Atlas (CGGA) data. In general, the expression of SAT1 is different between most tumors and their adjacent normal tissues. The results demonstrated that SAT1 expression is positively associated with TMB in LGG, BRCA, and THYM. The results displayed that the expression level of SAT1 is obviously correlated with the level of infiltrating macrophages and CD8 + T cells, and the levels of most immune gene sets were associated with the SAT1 expression in LGG. Interestingly, univariate and multivariate models significantly indicated that the OS and PFI of patients with LGG with high SAT1 levels were poorer than those with low SAT1 expression in the TCGA LGG cohort. GSEA showed that SAT1 was involved in immune regulation and multiple signaling pathways. Finally, our analysis demonstrated that SAT1 was closely associated with IDH mutation, 1p19q codeletion, chemoradiotherapy resistance and disease recurrence. Abundant expression of SAT1 was related to poor disease prognosis and abundant immune cell infiltration in LGG.
      datePublished:2022-02-28T00:00:00Z
      dateModified:2022-02-28T00:00:00Z
      pageStart:1
      pageEnd:15
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12885-022-09313-w
      keywords:
         Ferroptosis
         SAT1
         Low-grade glioma
         Pan-cancer
         Immune cells
         Immune checkpoint
         Drug resistance
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig7_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig8_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig9_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-022-09313-w/MediaObjects/12885_2022_9313_Fig10_HTML.png
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:22
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yanhua Mou
            affiliation:
                  name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
                  address:
                     name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lu Zhang
            affiliation:
                  name:First Affiliated Hospital of Anhui Medical University
                  address:
                     name:Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zhantao Liu
            affiliation:
                  name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
                  address:
                     name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Xiujun Song
            affiliation:
                  name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
                  address:
                     name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:22
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
      address:
         name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
         type:PostalAddress
      name:First Affiliated Hospital of Anhui Medical University
      address:
         name:Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China
         type:PostalAddress
      name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
      address:
         name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
         type:PostalAddress
      name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
      address:
         name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yanhua Mou
      affiliation:
            name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
            address:
               name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
               type:PostalAddress
            type:Organization
      name:Lu Zhang
      affiliation:
            name:First Affiliated Hospital of Anhui Medical University
            address:
               name:Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China
               type:PostalAddress
            type:Organization
      name:Zhantao Liu
      affiliation:
            name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
            address:
               name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Xiujun Song
      affiliation:
            name:Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
            address:
               name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
      name:Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China
      name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China
      name:Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China

Social Networks {👍}(1)

https://link.springer.com/article/10.1186/s12885-022-09313-w/mailto:[email protected]

External Links {🔗}(198)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.58s.

LINK . SPRINGER . COM {}